Risk of psoriasis in patients treated with dupilumab for bullous pemphigoid: A cohort study

By afschroeder • September 19, 2026

Curman P, Thapa M, Ludwig RJ, Kasperkiewicz M. Risk of psoriasis in patients treated with dupilumab for bullous pemphigoid: A cohort study. J Eur Acad Dermatol Venereol. 2026 Sep 19. doi: 10.1111/jdv.70759. Epub ahead of print. PMID: 42760847.

Tags: bullous pemphigoid, Dermatology, Dupilumab, Epidemiology, psoriasis, Publications

Temporal CRAC channel blockade modulates the MYC-MXD axis to attenuate autoimmune inflammation

Wu B, Hasiakos S, Cokus S, Do M, Kaplan E, Pellegrini M, Sun Z, Kim RH, Srikanth S, Gwack Y. Temporal CRAC channel blockade modulates[...]

Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: Analysis of the UNCOVER-3 Study

Armstrong A, Merola JF, Chughtai R, Fotiou K, Ngantcha M, Sabatino S, Megna M, Man X, Honma M, Carrascosa JM, Pinter A. Early and Maintained[...]

Letter: Patch Test Utilization by Provider Type in the U.S. Commercially Insured Population, 2014-2024: Dermatologists on the Decline

Smart K, Armstrong AW, Adler BL. Letter: Patch Test Utilization by Provider Type in the U.S. Commercially Insured Population, 2014-2024: Dermatologists on the Decline. Dermatitis. 2026 Sep[...]